Regulated information

Q1 2017 sales stable at €86.1 million

Consolidated sales for Q1 2017 amounted to €86.1 million, up 0.4% as reported from the same period last year. Sales were boosted by a 1.8% positive currency impact mainly related to non-European currencies. Q1 sales fell 1.4% like-for-like. 

Q3 2014 sales up 11.0%

The Vétoquinol Group reported Q3 2014 sales of €82.2 million, up 11.0% compared to the same period last year (up 11.1% at constant exchange rates).

Q3 2017 sales of €88.3 million, up 5.2% at constant exchange rates

For the third quarter of 2017, the Vetoquinol Group posted sales of €88.3 million, up 5.2% from Q3 2016 at constant exchange rates.

2016 sales: €350.3 million 4.3% like-for-like growth

The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%.

Vétoquinol and Bioniche Life Sciences Inc. close sale of Bioniche Animal Health business

Lure, France and Belleville, Ontario, Canada, April 16, 2014 - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced the closing of the sale of Bioniche’s Animal Health business to Vétoquinol. The two companies announced the signing of a share purchase agreement in February that was subject to the approval of Bioniche shareholders. At a Special Meeting of Shareholders held yesterday, 97.4% of the Shares that were voted were in favour of the transaction.

Reference products up 2.2% in Q1 2014

Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012.

7.8% organic growth in Q4 2013

The Vétoquinol Group posted Q4 2013 sales of €80.1 million, up +7.8% like for like from Q4 2012.